The European Medicines Agency EMA gave the green light on Monday for the corona vaccine from Pfizer and BioNTech, which is adapted to the omikron subvariants BA.4 and BA.5. These are currently responsible for the lion’s share of infections.
For its decision, the EMA relied on the data related to the modified corona vaccine to the BA.1-omikron subvariant. The drug watchdog believes that the vaccines are closely related. The only difference is that this bivalent vaccine targets more recent omikron subvariants.
The modified vaccine may be administered to anyone from the age of twelve who has completed at least a basic vaccination schedule.
The modified omikron vaccine has already been given the green light in the United States. In early September, the EMA also approved vaccines from Pfizer and Moderna that were adapted to the BA.1-omikron subvariant.
The European Commission still has to formally approve the market authorization, but that is only a formality.
Free unlimited access to Showbytes? Which can!
Log in or create an account and don’t miss out on any of the stars.